Neutra Corp (NTRR)

$0.00 0.00 (N/A)
Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 1,537,800
Avg Vol 4,013,216
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 0%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Neutra Corp. researches, develops, and provides hemp-derived products in the nutraceutical space in the United States. The company sells hemp-derived products, including products containing delta-8-THC and other cannabinoids, CBD sports creams, and other products. Neutra Corp. was incorporated in 2011 and is based in Houston, Texas.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 307 228 1488
Address:
2500 CityWest Boulevard, Ste 150-161, Houston, United States
JayB79
JayB79 Jun. 13 at 11:41 AM
$NTRR https://www.otcmarkets.com/file/company/financial-report/572606/content
0 · Reply
JayB79
JayB79 Jun. 13 at 11:39 AM
$NTRR 3 of 3 Great Q1 report. Revenue growth, profitability, positive cash flow, no dilution, and a reduction in outstanding shares are all steps in the right direction. Still work to do, but it’s good to see progress and execution from the NLS team. Looking forward to seeing what Q2 brings.
0 · Reply
JayB79
JayB79 Jun. 13 at 11:38 AM
$NTRR 2 of 3 CASH Position Cash increased from about $36,743 at January 31, 2026 to $49,910 at April 30, 2026. Operating activities generated positive cash flow of approximately $65,284. Balance Sheet Concerns The company still has: Management specifically states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Neutra Life Sciences Continues to Drive the Story The filing confirms that the clinical research subsidiary, Neutra Life Sciences (NLS), is now the primary growth engine. NLS operates clinical research sites across multiple specialties and generated the vast majority of Q1 revenue. My Overall Assessment For NTRR shareholders, this was probably the strongest quarterly filing in years because:
0 · Reply
JayB79
JayB79 Jun. 13 at 11:37 AM
$NTRR 1 of 3 Quick overview: The Big Positive: Revenue Growth Revenue jumped to $352,811 versus $68,057 in the same quarter last year — an increase of more than 400%. Most of the revenue came from the Neutra Life Sciences clinical research business, which generated approximately $325,811 during the quarter. Profitability The company reported a net profit of $84,505, compared to a loss of $109,023 in the prior-year quarter. This is a significant improvement and one of the strongest numbers shareholders have seen from NTRR. No Dilution During the Quarter Common shares outstanding remained at 2.917 billion shares, the same as the previous quarter. No new common stock was issued during Q1. Share Cancellation The company disclosed that 125 million shares were cancelled in February 2026 after a service agreement with Pacific Capital Markets was terminated.
0 · Reply
JayB79
JayB79 Jun. 13 at 11:35 AM
$NTRR
0 · Reply
Toph788
Toph788 Mar. 30 at 10:00 PM
$NTRR https://www.otcmarkets.com/file/company/financial-report/546109/content
0 · Reply
NotMeAgain
NotMeAgain Feb. 10 at 6:40 PM
$NTRR Sydney in prison yet or is he out on bail? Asking for a friend.
0 · Reply
Toph788
Toph788 Jan. 22 at 3:18 PM
$NTRR https://finance.yahoo.com/news/neutra-corp-successfully-pivots-business-120000372.html
0 · Reply
NotMeAgain
NotMeAgain Jan. 15 at 8:20 PM
$NTRR What a fkn crook Sydney is. Now he has diluted to the tune of 3.05 billion shares, and he has no way to pay those loans back other than trying to find another sucker to sell shares to so he will be diluting even further since he set it up so the authorized shares is "unlimited". The dude should be in prison.
0 · Reply
Toph788
Toph788 Jan. 13 at 5:23 PM
$NTRR https://www.otcmarkets.com/file/company/financial-report/515701/content
0 · Reply
Latest News on NTRR
No data available.
JayB79
JayB79 Jun. 13 at 11:41 AM
$NTRR https://www.otcmarkets.com/file/company/financial-report/572606/content
0 · Reply
JayB79
JayB79 Jun. 13 at 11:39 AM
$NTRR 3 of 3 Great Q1 report. Revenue growth, profitability, positive cash flow, no dilution, and a reduction in outstanding shares are all steps in the right direction. Still work to do, but it’s good to see progress and execution from the NLS team. Looking forward to seeing what Q2 brings.
0 · Reply
JayB79
JayB79 Jun. 13 at 11:38 AM
$NTRR 2 of 3 CASH Position Cash increased from about $36,743 at January 31, 2026 to $49,910 at April 30, 2026. Operating activities generated positive cash flow of approximately $65,284. Balance Sheet Concerns The company still has: Management specifically states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Neutra Life Sciences Continues to Drive the Story The filing confirms that the clinical research subsidiary, Neutra Life Sciences (NLS), is now the primary growth engine. NLS operates clinical research sites across multiple specialties and generated the vast majority of Q1 revenue. My Overall Assessment For NTRR shareholders, this was probably the strongest quarterly filing in years because:
0 · Reply
JayB79
JayB79 Jun. 13 at 11:37 AM
$NTRR 1 of 3 Quick overview: The Big Positive: Revenue Growth Revenue jumped to $352,811 versus $68,057 in the same quarter last year — an increase of more than 400%. Most of the revenue came from the Neutra Life Sciences clinical research business, which generated approximately $325,811 during the quarter. Profitability The company reported a net profit of $84,505, compared to a loss of $109,023 in the prior-year quarter. This is a significant improvement and one of the strongest numbers shareholders have seen from NTRR. No Dilution During the Quarter Common shares outstanding remained at 2.917 billion shares, the same as the previous quarter. No new common stock was issued during Q1. Share Cancellation The company disclosed that 125 million shares were cancelled in February 2026 after a service agreement with Pacific Capital Markets was terminated.
0 · Reply
JayB79
JayB79 Jun. 13 at 11:35 AM
$NTRR
0 · Reply
Toph788
Toph788 Mar. 30 at 10:00 PM
$NTRR https://www.otcmarkets.com/file/company/financial-report/546109/content
0 · Reply
NotMeAgain
NotMeAgain Feb. 10 at 6:40 PM
$NTRR Sydney in prison yet or is he out on bail? Asking for a friend.
0 · Reply
Toph788
Toph788 Jan. 22 at 3:18 PM
$NTRR https://finance.yahoo.com/news/neutra-corp-successfully-pivots-business-120000372.html
0 · Reply
NotMeAgain
NotMeAgain Jan. 15 at 8:20 PM
$NTRR What a fkn crook Sydney is. Now he has diluted to the tune of 3.05 billion shares, and he has no way to pay those loans back other than trying to find another sucker to sell shares to so he will be diluting even further since he set it up so the authorized shares is "unlimited". The dude should be in prison.
0 · Reply
Toph788
Toph788 Jan. 13 at 5:23 PM
$NTRR https://www.otcmarkets.com/file/company/financial-report/515701/content
0 · Reply
Toph788
Toph788 Oct. 31 at 10:21 AM
$NTRR https://finance.yahoo.com/news/neutra-corps-subsidiary-neutra-life-110000260.html?guccounter=1&guce_referrer=aHR0cHM6Ly9uZXV0cmFpbmMuY29tLw&guce_referrer_sig=AQAAALL8FFCcn3rr5cCDbF26OYERMlzPxoLQDyEg7kDudWWKpDYX3gHsultxn8cQn3vaFJ3hvzBOWnvYpQ8SBJloX7n_-Otter77ro_5ynCPUt-sLeX6wv7E-3IIYohVz90KX-13-jxMS9lSUHRpBrLzVcYG04XYhM84smaPMhD4ipAS
0 · Reply
Toph788
Toph788 Oct. 31 at 10:20 AM
$NTRR https://www.otcmarkets.com/file/company/financial-report/494349/content
0 · Reply
NotMeAgain
NotMeAgain Sep. 5 at 10:00 PM
$NTRR "driving sustainable growth and delivering meaningful results for our stakeholders". What "growth" and "results" are you referring to? The results of shareholders losing all their money? What a crock of BS. Sydney is a lying con man.
0 · Reply
JayB79
JayB79 Aug. 25 at 2:10 PM
$NTRR CuraConnector on hold. In addition, Neutra Corp. and CuraConnector.com have mutually agreed to defer any potential acquisition discussions and revisit the opportunity at a later time. This decision allows both parties to focus on their respective operational priorities while maintaining an open dialogue for future collaboration. "Our priority right now is to build momentum within Neutra Life Sciences and scale our site management operations," said Sydney Jim. "By deferring acquisition talks, we ensure that our resources and attention are dedicated to driving sustainable growth and delivering meaningful results for our stakeholders."
0 · Reply
JayB79
JayB79 Aug. 25 at 10:55 AM
$NTRR Updated website. VIVIS now removed. https://neutrainc.com/
0 · Reply
NotMeAgain
NotMeAgain Aug. 14 at 8:01 PM
$NTRR Sydney scamming shareholders one bs lie at a time.
0 · Reply
jd_76
jd_76 Aug. 12 at 7:45 PM
$NTRR yeah we’re in trouble with all the weed news and we didn’t even freaking move
3 · Reply
JayB79
JayB79 Aug. 4 at 1:02 PM
$NTRR Neutra Corp's Subsidiary, Neutra Life Sciences, Expands Rapidly With New Joint Venture Partnerships https://x.com/corpneutra/status/1952345057165738425?s=46&t=0oBkpEBdmVv-_NnE0jX_yQ
0 · Reply
JayB79
JayB79 Jul. 25 at 9:14 PM
$NTRR CuraConnector update coming? More revenue streams? Guess we will see. 💚
1 · Reply
JayB79
JayB79 Jun. 30 at 11:51 AM
$NTRR Neutra Corp Reports Breakthrough First Quarter Following Launch of Its New Clinical Research Network | NTRR - Neutra Corp. | News | OTC Markets https://www.otcmarkets.com/stock/NTRR/news/Neutra-Corp-Reports-Breakthrough-First-Quarter-Following-Launch-of-Its-New-Clinical-Research-Network?id=484336
1 · Reply
JayB79
JayB79 Jun. 19 at 6:40 PM
$NTRR Q Filed https://www.otcmarkets.com/file/company/financial-report/475321/content
0 · Reply
Panicman
Panicman Jun. 17 at 12:29 PM
$NTRR let's hope something happens here i have a long way to go to just get even!
1 · Reply